Subfatin, Asprosin, Alamandine and Maresin-1 Inflammation Molecules in Cardiopulmonary Bypass

Figures & data

Table 1 Certain Demographic Characteristics and Biochemical Parameters of the Participants

Parameters	CPB	Control	p
Age (year)	69.2 ± 3.2	66.4 ± 5.1	0.08
Sex (male/female)	11/8	10/9	0.09
BMI (kg/m^2)	31.7 ± 2.8	29.3 ± 2.9	0.07
Glucose (mmol/L)	5.41 ± 0.45	5.08 ± 0.31	0.06
Calcium (mmol/L)	2.48 ± 0.17	2.4 ± 0.22	0.09
Potassium (mEq/mL)	4.62 ± 0.1	4.42 ± 0.2	0.09
Sodium (mEq/mL)	142.7 ± 3.1	139.8.7 ± 2.4	0.08
HDL-C (mmol/L)	1.19 ± 0.11	1.22 ± 0.11	0.06
LDL-C (mmol/L)	4.2 ± 0.73	4.0± 0.77	0.06
Triglycerides (mmol/L)	2.69± 0.21	2.12± 0.26	0.06
Creatine (umol/L)	113.18±53.05	97.26 ±79.58	0.06

Note: Control group vs CPB group (p>0.05).

Abbreviations: BMI, Body Mass Index; CPB, Cardiopulmonary bypass. HDL-C, high-density lipoprotein cholesterol; LDL-C, Low-density lipoprotein cholesterol.

Figure 1 Flowchart of participants’ progress through the phases of the trial.

Table 2 Operative Characteristics of CPB Patients

Parameters	EF (%)	BSA (m^2)	CPBT (min)	CCT (min)	GN	Total LOS
Values	47.8 ± 4.6	1.9 ± 0.2	153 ± 7	98 ± 2	3.9 ± 0.4	7.9 ± 1

Abbreviations: BSA, body surface area; CCT, Cross-clamp time; CPBT, Cardiopulmonary bypass time; EF, Ejection fraction; GN, Graft number; LOS, length of hospital stays.

Table 3 Change in Hemodynamic Data of Patients Over Time

Parameters	CVP (mmHg)	HR (Pulse min)	MAP (mmHg)	MPAP (mmHg)	PCWP (mmHg)
T1	8.0	89	100	25	15
T2	6.7	77	76	22	14
T3	6.3	0.0	42	21	13
T4	6.4	91	79	22	14
T5	7.8	88	89	22	14
T6	7.9	89	92	23	15
T7	8.0	89	91	23	15

Abbreviations: CVP, central venous pressure; HR: Heart Rate; MAP, mean arterial pressure; MPAP, mean pulmonary arterial pressure; PCWP, central venous pressure; T1, before anesthesia induction; T2, before cardiopulmonary bypass; T3, 5 min before cross-clamping; T4, 5 min after cross-clamping; T5, when taken to intensive care; T6, Postoperative 24th hour; T7, 72nd hour.

Table 4 History of Drug Use in Patients with Cardiopulmonary Bypass (CPB) and Control

Drugs	CPB	Control
Metoprolol tartrate (25 mg orally twice a day)	19 from 19	0 from 19
Acetylsalicylic acid (100 mg orally/day)	19 from 19	0 from 19
Ramipril (2.5 mg orally/day)	13 from 19	0 from 19
Furosemides (40 mg orally/day)	6 from 19	0 from 19
Atorvastatin (20 mg orally/day)	14 from 19	0 from 19

Abbreviation: CPB, Cardiopulmonary bypass.

Figure 2 Comparison of Subfatin (A), maresin-1 (B), asprosin (C), and alamandine (D) changes of CPB patients according to time periods in before, during and after surgical operation and with control. (C) Control; CPB: Cardiopulmonary bypass; T1: Before anesthesia induction; T2: Before cardiopulmonary bypass; T3: 5 minutes before cross-clamping; T4: 5 minutes after cross-clamping; T5: When taken to intensive care; and T6: Postoperative 24th hour; T7: 72nd hour; a: (T1; T2; T3; T4; T5; T6; T7) group versus control group (p < 0.05). b: (T2; T3; T4; T5; T6; T7) group versus T1 group (p < 0.05). ab: (T4; T5; T6; T7) group versus T3 group (p < 0.05).

Data Sharing Statement

Data for this study can be obtained from the corresponding authors upon reasonable request.